Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207M
-
Number of holders
-
143
-
Total 13F shares, excl. options
-
26.9M
-
Shares change
-
-1.42M
-
Total reported value, excl. options
-
$987M
-
Value change
-
-$72.1M
-
Put/Call ratio
-
1.02
-
Number of buys
-
58
-
Number of sells
-
-79
-
Price
-
$36.66
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2019
199 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2019.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 143 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.9M shares
of 207M outstanding shares and own 12.98% of the company stock.
Largest 10 shareholders include Bellevue Group AG (4.24M shares), Meditor Group Ltd (2.68M shares), VANGUARD GROUP INC (2.67M shares), Pentwater Capital Management LP (2.48M shares), BlackRock Inc. (2.12M shares), STATE STREET CORP (1.44M shares), BOXER CAPITAL, LLC (975K shares), CREDIT SUISSE AG/ (953K shares), Rhenman & Partners Asset Management AB (656K shares), and WASATCH ADVISORS INC (630K shares).
This table shows the top 143 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.